Together with the observation of high c-Src levels in patients with relapses, our data suggest a clinical benefit of c-Src inhibition in LBC patients, advocating the evaluation of c-Src inhibitors as novel chemotherapeutic options in lobular carcinoma. This evidence concerns the gene SRC and CDH1-related diffuse gastric and lobular breast cancer syndrome.